Marco Donia

Best Publications

• Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

  Rita Cabrita;Martin Lauss;Adriana Sanna;Marco Donia

  2148
  Citations

• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf

  691
  Citations

• Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

  Unknown

  571
  Citations

• Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

  Martin Lauss;Marco Donia;Katja Harbst;Rikke Andersen

  502
  Citations

• Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

  Erlend Strønen;Erlend Strønen;Mireille Toebes;Sander Kelderman;Marit M. Van Buuren

  496
  Citations

• Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

  Sine Reker Hadrup;Marco Donia;Per Thor Straten

  395
  Citations

• Collagen density regulates the activity of tumor-infiltrating T cells

  Dorota E. Kuczek;Anne Mette Hvid Larsen;Anne Mette Hvid Larsen;Marie-Louise Thorseth;Marco Carretta

  381
  Citations

• Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

  Amalie Kai Bentzen;Andrea Marion Marquard;Rikke Lyngaa;Sunil Kumar Saini

  362
  Citations

• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

  Rikke Andersen;Marco Donia;Eva Ellebaek;Troels Holz Borch

  323
  Citations

• Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

  Michael D. Crowther;Garry Dolton;Mateusz Legut;Marine E. Caillaud

  244
  Citations

• Principles of adoptive T cell therapy in cancer.

  Özcan Met;Özcan Met;Kasper Mølgaard Jensen;Christopher Aled Chamberlain;Marco Donia

  224
  Citations

• Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

  Eva Ellebaek;Trine Zeeberg Iversen;Niels Junker;Marco Donia;Marco Donia

  204
  Citations

• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

  Unknown

  197
  Citations

• Dissection of T cell antigen specificity in human melanoma

  Rikke Sick Andersen;Charlotte Albæk Thrue;Niels Junker;Rikke Birgitte Lyngaa

  194
  Citations

• Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

  Henrik Jespersen;Mattias F. Lindberg;Marco Donia;Elin M. V. Söderberg

  166
  Citations

• The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

  Stephen L. Abrams;Linda S. Steelman;John G. Shelton;Ellis W.T. Wong

  159
  Citations

• Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

  M.H. Geukes Foppen;M. Donia;I.M. Svane;J.B.A.G. Haanen

  156
  Citations

• More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers

  Garry Michael Dolton;Katie Tungatt;Angharad Lloyd;Valentina Bianchi

  154
  Citations

• Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

  Marco Donia;Marco Donia;Rikke Andersen;Julie Westerlin Kjeldsen;Paolo Fagone

  150
  Citations

• Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

  Unknown

  131
  Citations